Pharma Deals Review, Vol 2007, No 89 (2007)

Font Size:  Small  Medium  Large

Synta’s GSK Deal No Investor Surprise

Business Review Editor

Abstract


GlaxoSmithKline (GSK) has entered into a global alliance with Synta Pharmaceuticals to develop a drug, elesclomol (STA-4783) for the treatment of metastatic melanoma. The deal could worth up to US$1010 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.